Under the Skin: Autoimmunity and Type 2 Inflammation in Bullous Pemphigoid (BP)

No matches

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region

Under the Skin: Autoimmunity and Type 2 Inflammation in Bullous Pemphigoid (BP)

Related resources

Bullous Pemphigoid (BP): Don't Miss the Diagnosis

Navigating Atopic Dermatitis and Hand and Foot Dermatitis: Clinical Manifestations and Pathophysiology

Disease Modification Concepts in AD

Barrier disruption in AD and the development of environmental and food allergies

How type 2 cytokines can amplify inflammatory response in CSU

Bullous Pemphigoid Mechanism of Disease Video

Diagnosis of Bullous Pemphigoid Interactive Patient Case

Differential Diagnosis and Disease Onset in Older Adult Patients With AD

Importance of Achieving Disease Control in Adults With Moderate-to-Severe AD

New Data on the Systemic (Multi-Organ) Burden of AD in Children and the Need for Early Intervention

The Benefits of Early Intervention in AD: More Than Skin Deep

The Benefits of Early Intervention in AD: More Than Skin Deep – Q&A Session and Conclusion

The Cumulative Disease Burden of AD in Adult Patients

What do we mean by disease control in AD?

ADVENT On Air | First-hand Experience: Practical Insights On the Diagnosis and Assessment of Atopic Dermatitis of the Hands and Feet

ADVENT On Air | Exploring PN as a Distinct and Unique Disease

The Patient Burden of Chronic Pruritus of Unknown Origin (CPUO)

Stepping Into Hand and Foot Dermatitis

Understanding Disease Mechanisms

Guideline-Based Diagnosis of Atopic Dermatitis

Etiology and Diagnosis of Bullous Pemphigoid

Pathophysiology of Blister Formation in Bullous Pemphigoid

Unmet Needs for Bullous Pemphigoid (BP): Limitations of Diagnosis and Conventional Therapies

What We Know About Bullous Pemphigoid (BP): Challenges of the Various Clinical Manifestations, Diagnosis, and Burden for Patients and Caregivers

Mechanisms of Disease: Autoimmunity and Role of Type 2 Inflammation in Bullous Pemphigoid (BP)

ADVENT On Air | Getting to Grips With Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients?

Factors Contributing to Diagnostic Delays in Bullous Pemphigoid

Scratching the Surface: Understanding Itch in Prurigo Nodularis

What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?

Unveiling Atopic Dermatitis

Identification and Management of AD Uncontrolled With Topical Therapies in Children

Epidemiology and Pathophysiology of AD in Children

Key Treatment Considerations for Management of Atopic Dermatitis in Children

Role of Type 2 Inflammation in Skin Barrier Disruption and Itch

Under the Skin: Considerations for Atopic Dermatitis and Prurigo Nodularis in Clinical Practice

Type 2 Inflammation: A Common Link Between Atopic Dermatitis and Prurigo Nodularis

A Tale of Two Itches: Bridging the Gap With Type 2 Inflammation in Prurigo Nodularis and Chronic Spontaneous Urticaria

Itch and Inflammation in Two Distinct Diseases: PN and CSU

Connecting the Dots: Novel Insights on Type 2 Cytokines Mediating Neuroimmune Dysregulation in PN and CSU

The Journey of Diagnosis: Disease Burden and Diagnostic Considerations for Atopic Dermatitis and Prurigo Nodularis

Overview of Prurigo Nodularis Part 1: Clinical Features, Epidemiology, and Diagnosis

Overview of Prurigo Nodularis Part 2: Burden of Disease and Considerations of Patient Care

Role of Type 2 Inflammation in Prurigo Nodularis Part 1: Overview of Type 2 Inflammation

Role of Type 2 Inflammation in Prurigo Nodularis Part 2: Itch and Skin Lesions

Prurigo Nodularis Myths and Facts

ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis

Chronic Spontaneous Urticaria Mechanism of Disease Animation

Potential for Disease Modification in Atopic Dermatitis

Learning objectives

About these experts

Teri Greiling

Victoria Werth